CATX
Perspective Therapeutics, Inc.
$3.98
+0.11
(+2.84%)
Mkt Cap
307.45M
Volume
1,601,516
52W Range
1.96-6.16
Sector
Healthcare
Beta
1.76
EPS (TTM)
-1.41
P/E Ratio
-1.97
Revenue (TTM)
575,000
Rev Growth (5Y)
-35.3%
EPS Growth (5Y)
N/A
Company Description
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.43M | 7.10M | 10.79M | 10.05M | 9.68M | 7.31M | 5.92M | 4.76M | 4.77M | 4.61M |
| Net Income | (103.12M) | (79.28M) | (46.51M) | (14.67M) | (7.15M) | (3.19M) | (3.27M) | (4.85M) | (6.70M) | (6.16M) | (4.71M) | (3.68M) |
| EPS | -1.40 | -1.23 | -0.85 | -0.27 | -0.13 | -0.06 | -0.05 | -0.07 | -0.12 | -0.11 | -0.09 | -0.07 |
| Free Cash Flow | (95.23M) | (72.71M) | (37.98M) | (12.47M) | (7.98M) | (3.22M) | (3.91M) | (5.49M) | (6.05M) | (6.26M) | N/A | N/A |
| FCF / Share | -1.29 | -1.13 | -0.69 | -0.23 | -0.15 | -0.06 | -0.06 | -0.08 | -0.11 | -0.11 | N/A | N/A |
| Operating CF | (82.48M) | (18.29M) | (36.91M) | (12.17M) | (7.71M) | (2.84M) | (3.64M) | (5.05M) | (5.71M) | (5.71M) | N/A | N/A |
| Total Assets | 266.97M | 341.10M | 97.89M | 58.09M | 67.25M | 15.51M | 8.70M | 9.42M | 7.46M | 12.27M | N/A | N/A |
| Total Debt | 1.63M | 4.06M | 2.55M | 0 | 652,000 | 897,000 | 1.00M | 0 | 0 | 0 | N/A | N/A |
| Cash & Equiv | 30.63M | 61.58M | 9.24M | 20.99M | 60.35M | 9.59M | 2.39M | 5.33M | 2.60M | 5.93M | N/A | N/A |
| Book Value | 207.03M | 290.67M | 75.18M | 54.64M | 64.39M | 12.77M | 5.72M | 7.68M | 5.03M | 10.60M | N/A | N/A |
| Return on Equity | -0.50 | -0.27 | -0.62 | -0.27 | -0.11 | -0.25 | -0.57 | -0.63 | -1.33 | -0.58 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76,000 | 0 | 209,000 | 290,000 | 0 | 0 | 0 | 0 | 0 | 337,000 | 1.91M | 1.50M |
| Net Income | (26.19M) | (37.49M) | (25.97M) | (21.48M) | (18.18M) | (40.17M) | (15.12M) | (11.70M) | (12.28M) | (24.68M) | (10.36M) | (11.11M) |
| EPS | -0.25 | -0.51 | -0.35 | -0.30 | -0.25 | -0.57 | -0.21 | -0.18 | -0.25 | -0.45 | -0.19 | -0.20 |
| Free Cash Flow | (38.33M) | (29.73M) | (18.28M) | (20.98M) | (26.24M) | (41.22M) | (26.35M) | (9.92M) | 4.78M | (9.10M) | (10.34M) | (8.63M) |
| FCF / Share | -0.37 | -0.40 | -0.25 | -0.30 | -0.36 | -0.58 | -0.37 | -0.15 | 0.10 | -0.17 | -0.19 | -0.16 |
| Operating CF | (31.47M) | (24.66M) | (16.29M) | (19.95M) | (21.58M) | (26.61M) | 3.37M | (8.90M) | 13.85M | (9.01M) | (10.11M) | (8.07M) |
| Total Assets | 410.77M | 266.97M | 294.82M | 310.73M | 329.35M | 341.10M | 391.15M | 385.92M | 278.29M | 97.89M | 110.52M | 120.14M |
| Total Debt | 2.62M | 1.63M | 3.31M | 3.57M | 3.82M | 4.06M | 4.27M | 3.88M | 2.88M | 2.55M | 3.31M | 2.58M |
| Cash & Equiv | 53.97M | 30.63M | 26.76M | 28.85M | 44.41M | 61.58M | 226.44M | 252.00M | 142.12M | 9.24M | 17.98M | 28.32M |
| Book Value | 347.44M | 207.03M | 242.22M | 265.69M | 284.64M | 290.67M | 328.47M | 341.00M | 229.89M | 75.18M | 98.77M | 108.65M |
| Return on Equity | -0.08 | -0.18 | -0.11 | -0.08 | -0.06 | -0.14 | -0.05 | -0.03 | -0.05 | -0.33 | -0.10 | -0.10 |
CATX News
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
Perspective Therapeutics, Inc. (CATX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field
Perspective Therapeutics to Provide Several Upcoming Corporate Updates
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
Perspective Therapeutics to Participate in Upcoming Investor Conferences
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results